These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 4017947

  • 1. An evaluation of the role of antiestrogen-binding sites in mediating the growth modulatory effects of antiestrogens: studies using t-butylphenoxyethyl diethylamine, a compound lacking affinity for the estrogen receptor.
    Sheen YY, Simpson DM, Katzenellenbogen BS.
    Endocrinology; 1985 Aug; 117(2):561-4. PubMed ID: 4017947
    [Abstract] [Full Text] [Related]

  • 2. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
    Miller MA, Lippman ME, Katzenellenbogen BS.
    Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
    [Abstract] [Full Text] [Related]

  • 3. Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity.
    Pavlik EJ, Nelson K, Srinivasan S, Powell DE, Kenady DE, DePriest PD, Gallion HH, van Nagell JR.
    Cancer Res; 1992 Aug 01; 52(15):4106-12. PubMed ID: 1638522
    [Abstract] [Full Text] [Related]

  • 4. Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites.
    Katzenellenbogen BS, Miller MA, Mullick A, Sheen YY.
    Breast Cancer Res Treat; 1985 Aug 01; 5(3):231-43. PubMed ID: 4027393
    [Abstract] [Full Text] [Related]

  • 5. Antiestrogen pharmacology and mechanism of action.
    Katzenellenbogen BS, Miller MA, Eckert RL, Sudo K.
    J Steroid Biochem; 1983 Jul 01; 19(1A):59-68. PubMed ID: 6887873
    [Abstract] [Full Text] [Related]

  • 6. Studies on the ligand specificity and potential identity of microsomal antiestrogen-binding sites.
    Watts CK, Sutherland RL.
    Mol Pharmacol; 1987 May 01; 31(5):541-51. PubMed ID: 3553893
    [Abstract] [Full Text] [Related]

  • 7. Physicochemical and genetic evidence for specific antiestrogen binding sites.
    Faye JC, Jozan S, Redeuilh G, Baulieu EE, Bayard F.
    Proc Natl Acad Sci U S A; 1983 Jun 01; 80(11):3158-62. PubMed ID: 6574477
    [Abstract] [Full Text] [Related]

  • 8. Estrogenic stimulation of the antiestrogen specific binding site in rat uterus and liver.
    Winneker RC, Clark JH.
    Endocrinology; 1983 Jun 01; 112(6):1910-5. PubMed ID: 6682755
    [Abstract] [Full Text] [Related]

  • 9. Roles of antiestrogen binding sites in human endometrial cancer cells.
    Hayashida M, Terakawa N, Shimizu I, Ikegami H, Wakimoto H, Aono T, Tanizawa O, Matsumoto K.
    J Steroid Biochem; 1987 Jun 01; 26(6):705-11. PubMed ID: 3613570
    [Abstract] [Full Text] [Related]

  • 10. Histamine and growth: interaction of antiestrogen binding site ligands with a novel histamine site that may be associated with calcium channels.
    Brandes LJ, Bogdanovic RP, Cawker MD, LaBella FS.
    Cancer Res; 1987 Aug 01; 47(15):4025-31. PubMed ID: 2886214
    [Abstract] [Full Text] [Related]

  • 11. Tamoxifen inhibition of prolactin action in the mouse mammary gland.
    Biswas R, Vonderhaar BK.
    Endocrinology; 1991 Jan 01; 128(1):532-8. PubMed ID: 1846110
    [Abstract] [Full Text] [Related]

  • 12. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
    Sheen YY, Ruh TS, Mangel WF, Katzenellenbogen BS.
    Cancer Res; 1985 Sep 01; 45(9):4192-9. PubMed ID: 4040807
    [Abstract] [Full Text] [Related]

  • 13. Antitumor activity of clomiphene analogs in vitro: relationship to affinity for the estrogen receptor and another high affinity antiestrogen-binding site.
    Murphy LC, Sutherland RL.
    J Clin Endocrinol Metab; 1983 Aug 01; 57(2):373-9. PubMed ID: 6408114
    [Abstract] [Full Text] [Related]

  • 14. Antiestrogen inhibition of prolactin-induced growth of the Nb2 rat lymphoma cell line.
    Biswas R, Vonderhaar BK.
    Cancer Res; 1989 Nov 15; 49(22):6295-9. PubMed ID: 2804977
    [Abstract] [Full Text] [Related]

  • 15. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
    Greenberger LM, Annable T, Collins KI, Komm BS, Lyttle CR, Miller CP, Satyaswaroop PG, Zhang Y, Frost P.
    Clin Cancer Res; 2001 Oct 15; 7(10):3166-77. PubMed ID: 11595711
    [Abstract] [Full Text] [Related]

  • 16. The pure antiestrogen ICI 182,780 binds to a high-affinity site distinct from the estrogen receptor.
    Parisot JP, Hu XF, Sutherland RL, Wakeling A, Zalcberg JR, DeLuise M.
    Int J Cancer; 1995 Aug 09; 62(4):480-4. PubMed ID: 7635575
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
    Murphy CS, Parker CJ, McCague R, Jordan VC.
    Mol Pharmacol; 1991 Mar 09; 39(3):421-8. PubMed ID: 2005879
    [Abstract] [Full Text] [Related]

  • 20. Differential effects of tamoxifen and analogs with nonbasic side chains on cell proliferation in vitro.
    Murphy LC, Sutherland RL.
    Endocrinology; 1985 Mar 09; 116(3):1071-8. PubMed ID: 3971898
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.